In Mice Engineered to Keep Anandamide Around, THC Drove More Tolerance and Withdrawal | Research

The takeaway

FAAH knockout mice repeatedly given THC showed stronger tolerance, greater CB1 receptor dampening, and more precipitated withdrawal than mice given anandamide at equally effective doses.

Readers interested in the mechanics of cannabinoid tolerance and dependence, preclinical pharmacologists weighing direct CB1 agonists against strategies that elevate endocannabinoid tone, and anyone tracking how receptor efficacy shapes observed tolerance.

Less CB1 downregulation
after repeated anandamide than after THC in FAAH knockout mice, aligning with smaller behavioral tolerance and weaker precipitated withdrawal

What the researchers found

Repeated THC dosing shifted dose–response curves further to the right for classic cannabinoid effects in mice. That means it took more THC to achieve the same level of pain relief, catalepsy, and body temperature drop after a subchronic regimen. Anandamide produced smaller shifts under the same testing conditions in FAAH knockout mice, which are engineered so anandamide is not rapidly broken down.

Brain measures lined up with behavior. THC reduced CB1 receptor signaling capacity and receptor availability, shown by lower agonist-stimulated [35S]GTPγS binding in brain and spinal cord and reduced [3H]WIN55,212-2 binding in brain. Anandamide-treated mice showed less CB1 desensitization and downregulation.

Dependence signals diverged too. Giving the CB1 blocker rimonabant after repeated dosing precipitated a much smaller withdrawal syndrome in anandamide-dosed mice than in THC-dosed mice.

Cross-tolerance tests pointed to pharmacology at the receptor as a key driver. THC is a lower efficacy CB1 agonist than anandamide. When CB1 receptors were partially lost or desensitized, the behavioral effects of the lower efficacy drug dropped off more. The study argues that what you observe as tolerance during testing depends heavily on the intrinsic activity of the ligand being tested.

Why it matters

The study separates two ways of engaging the endocannabinoid system in mice. Repeated direct CB1 agonism with THC produced stronger tolerance, more receptor downregulation, and a clearer withdrawal signal. Elevating signaling via an endogenous ligand, anandamide, produced milder adaptations under parallel conditions in a model designed to keep anandamide from being rapidly degraded. For drug development that targets endocannabinoid tone rather than directly pushing the receptor, this mechanistic contrast is central.

The numbers in context

- Tolerance pattern: larger rightward shifts in THC dose–response curves than in anandamide curves for pain relief, catalepsy, and hypothermia. A rightward shift means a higher dose is needed to get the same effect.

- CB1 signaling: agonist-stimulated [35S]GTPγS binding was significantly reduced after repeated THC in brain and spinal cord. This indicates receptor desensitization.

- CB1 availability: [3H]WIN55,212-2 binding fell after repeated THC in brain, consistent with receptor downregulation.

- Dependence signal: rimonabant precipitated markedly smaller withdrawal in anandamide-dosed FAAH knockout mice than in THC-dosed mice.

How the study worked

Male FAAH knockout mice, which have impaired breakdown of anandamide, received subchronic dosing with either anandamide or THC at equi-active, maximally effective doses. Tolerance was quantified as rightward shifts in dose–effect curves for antinociception, catalepsy, and hypothermia. CB1 receptor function and density were assessed using agonist-stimulated [35S]GTPγS binding in brain and spinal cord and [3H]WIN55,212-2 binding in brain. Dependence was probed by precipitating withdrawal with the CB1 antagonist rimonabant after repeated dosing. Cross-tolerance experiments compared how prior exposure altered responses to each ligand. The abstract does not report sample size, dosing route, or exact dosing schedules.

Who was studied

FAAH(-/-) mice, species not specified, Country not specified.

What this study cannot tell us

This is an animal study in a genetically modified model where FAAH is absent. That elevates anandamide and other FAAH substrates in ways that do not mirror typical physiology. Only males were studied. The abstract does not report sample sizes, dosing routes, or exact dosing intervals, which makes it hard to gauge effect sizes and reproducibility. Behavioral outcomes were limited to the classic rodent tetrad, which captures only a slice of cannabinoid effects. Withdrawal was defined by antagonist-precipitated signs, an operational model that may not map onto other dependence measures. Anandamide and THC differ in more than efficacy, including metabolism and signaling kinetics, which could contribute to the adaptation differences.

How to read the evidence

Rated preliminary: controlled mechanistic work with receptor assays in mice provides strong internal validity, but the FAAH knockout model, limited behavioral endpoints, and lack of reported sample sizes narrow generalizability.

When this study was published

Published in 2010, before later human programs tested FAAH inhibition with mixed outcomes and safety concerns for some compounds. The receptor-level insights remain relevant, but translation to people is uncertain.

The bigger picture

Cannabinoid tolerance is often discussed as one thing. This mouse work shows it is not. The extent of behavioral tolerance depends on the ligand’s intrinsic efficacy at CB1 during testing and on how the receptor system adapts to the prior regimen. In these experiments, direct CB1 stimulation by THC pushed the system toward desensitization and downregulation. Sustained enhancement of an endogenous ligand produced a softer footprint on the receptor system in this model. Those differences frame why elevating endocannabinoid tone and administering a CB1 agonist can land in different places, even if both act through the same receptor family.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Would similar tolerance and receptor adaptation patterns appear in wild-type mice given a FAAH inhibitor rather than in FAAH knockouts?
Do other high efficacy CB1 agonists resemble anandamide in being less sensitive to receptor loss at test, or is this ligand-specific?
How do brain region specific changes in CB1 signaling track with particular behavioral tolerance components?
What happens to these adaptation patterns with longer dosing schedules or lower, clinically relevant exposures?
How does 2-AG, the other major endocannabinoid, fit into this tolerance and desensitization framework?

Common questions

What is FAAH and why use FAAH knockout mice?

FAAH is the enzyme that rapidly breaks down anandamide. Knocking it out keeps anandamide around longer, allowing repeated anandamide dosing to be studied without it vanishing immediately.

What does a rightward shift in a dose–response curve mean?

It means tolerance. A higher dose is needed to produce the same effect that a lower dose produced before.

Did anandamide cause dependence in this study?

When researchers gave the CB1 blocker rimonabant after repeated dosing, withdrawal signs were much smaller in anandamide-dosed mice than in THC-dosed mice in this model.

Read the original research

FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(8), 1775-87

Neuropsychopharmacology is a reputable journal published by the American College of Neuropsychopharmacology.

View on PubMed ↗Publisher’s paper ↗

Citation

Falenski, Katherine W; Thorpe, Andrew J; Schlosburg, Joel E; Cravatt, Benjamin F; Abdullah, Rehab A; Smith, Tricia H; Selley, Dana E; Lichtman, Aron H; Sim-Selley, Laura J. (2010). FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(8), 1775-87. https://doi.org/10.1038/npp.2010.44